The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2008Mu Opioid Receptors as a Drug Target for Treating Motor Fluctuations in PD
Objective/Rationale:
Impaired gastric emptying is commonly found in Parkinson's disease and impacts the effectiveness of oral treatment given to PD patients. Blocking opiate receptors improves the anti...
-
Target Validation, 2008Dopaminergic Neuroprotection by Regulator of G-protein Signaling 10 (RGS10)
Objective/Rationale:
Nigral dopamine (DA) neurons are extremely sensitive to inflammatory stimuli; therefore, chronic neuroinflammation has been implicated in the pathogenesis of Parkinson's disease... -
Target Validation, 2008Validation of the NR2D Subunit of the NMDA Receptor as a Therapeutic Target for Parkinson's Disease
Objective/Rationale:
The NMDA receptor is a protein that helps to mediate communication between neurons. The brain makes several different kinds of NMDA receptors, sometimes termed NR2A, NR2B, NR2C... -
Target Validation, 2008NR2B as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
The loss of striatal dopamine that accompanies Parkinson’s disease disrupts the function of the neurotransmitter glutamate within this same region. Glutamate transmission involves...
-
Target Validation, 2008SIRT1 Activators as Therapy for Parkinson's Disease
Objective/Rationale:
Resveratrol is a compound that activates a protetin, SIRT1, which is known to protect against stresses associated with neurodegeneration, including oxidative damage and protein... -
Therapeutics Development Initiative, 2008Novel Gastric Retentive Controlled-release Dosage Forms of Levodopa/Carbidopa: in vivo Assessment in Pre-Clinical Models
Objective/Rationale:
The objective of this project is to develop gastric retentive controlled-release tablets of levodopa/carbidopa that will result in more constant blood levels of levodopa compared...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.